graph Evidence gap map comparisons
atezolizumab based treatmentavelumab based treatmentdurvalumab based treatmentnivolumab based treatmentpembrolizumab aloneanti-PD-(L)1
atezolizumab alone avelumab alone durvalumab alone durvalumab plus osimertinib nivolumab alone pembrolizumab (10mg/kg) pembrolizumab (2mg/kg) Tislelizumab
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population 5          
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant 1   
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative 1
mNSCLC - L2 - PDL1 positive 7             
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population 1   
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population 1   
squamous - mNSCLC - L2 - PDL1 positive
Comparator:  vs docetaxel;   vs osimertinib;   vs Standard of Care (SoC); 
Risk of bias:  low;   some concerns;   high;  NA;